Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Regulation Commercial M & A

FTC Tells Medtronic To Sell Intersect ENT Subsidiary To Avoid Monopoly

  • News

Executive Summary

The move removes all regulatory roadblocks to Medtronic’s $1.1bn acquisition of Intersect ENT, which was announced in August 2021.

You may also be interested in...



Dexcom Rumored To Be In Talks To Acquire Insulet

Dexcom may be planning to purchase Insulet to enter the insulin pump market and transform itself into a diabetes tech giant.

Medtronic Bolsters Sinus Portfolio With $1.1Bn Intersect ENT Buyout

Medtronic announced plans to acquire Intersect ENT, adding its sinus implants to Medtronic's portfolio of devices used by surgeons in treating chronic rhinosinusitis.

Warning Letters And Close-Outs – September 2023

It was a quiet month for warning letters at the FDA last month, with the agency issuing no new warning letters and closing out only one. 

Table

View full table

Topics

Related Companies

Tags:
Regulation Commercial M & A
Latest Headlines

Minute Insight: Medtronic May Sell Respiratory And Monitoring Units To Private Equity

Stakeholders Give FDA An Earful; Poor Communication, Recall Inefficiency, Patients At Risk

Global Medtech Guidance Tracker: September 2023

‘Build A Company To Be Bought, Not Sold,' 'Match The Asset To The Capital,' And Other Advice From VC Experts

See All
UsernamePublicRestriction

Register

MT145395

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By